New option available for treating head lice

August 2009
Infectious Diseases in Children;Aug2009, Vol. 22 Issue 8, p46
The article reports on the approval by the U.S. Food and Drug Administration on Ulesfia 5% benzyl alcohol lotion as the first non-neurotoxic topical head lice prescription treatment for use in children aged 6 months and older.


Related Articles

  • January and you still have head lice! Burnside, Mimi // Clinical Advisor;Jan2015, Vol. 18 Issue 1, p98 

    No abstract available.

  • Drugs in the News.  // Clarendon Enterprise (TX);5/14/2009, Vol. 20 Issue 20, p5 

    The article offers information on a drug for head lice which was approved by the U.S. Food and Drug Administration.

  • Labeling changes suggested for lice tx.  // Dermatology Times;May96, Vol. 17 Issue 5, p4 

    Reports that the Food and Drug Administration has recommended labeling changes for childhood lice treatments containing the pesticide lindane.

  • FDA approves topical lice treatment spinosad for patients aged 4 years and older.  // Infectious Diseases in Children;Feb2011, Vol. 24 Issue 2, p5 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the topical application of spinosad for head lice treatment in patients four years old and above.

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Apr2011 Clinical Brief, p2 

    The article reports on the drug approvals by the U.S. Food and Drug Administration (FDA). The FDA approved Spinosad for the treatment of head lice. The FDA issued an alert on the safety of the drug dronedarone (Multaq) approved for the prevention of atrial fibrillation because it has been...

  • Discovery Pipeline. Ritter, Amy // BioPharm International;Apr2012, Vol. 25 Issue 4, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the first allogenic cell-based therapy, called GINTUIT, which uses cells unrelated to the patient to create the therapeutic.

  • FDA research uncovers clues on serious diseases.  // FDA Consumer;Mar/Apr98, Vol. 32 Issue 2, p4 

    Presents the results of two studies that may change the way some life-threatening illnesses are treated published by US Food and Drug Administration. Name of the publications in which the results of the study have been published; Medical conditions in which this discovery may have potential...

  • Unapproved But Not Always Unavailable. Thompson, Larry // FDA Consumer;Jan/Feb2000, Vol. 34 Issue 1, p8 

    Discusses the issue of the availability of experimental treatments for seriously ill patients in the United States. Percent of drugs in testing that will ultimately be approved; Incorrect perception of the public about the Food and Drug Administration; Pros and cons of experimental treatments;...

  • Treatment Approved for Acute Bleeding Disorder.  // Clarendon Enterprise (TX);2/19/2009, Vol. 20 Issue 8, p10 

    The article reports that the U.S. Food and Drug Administration has approved the drug RiaSTAP to treat the rare bleeding disorder Congenital Fibrinogen Deficiency.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics